

Myb Sumoylation Site Antibody Blocking Peptide
Synthetic peptide
Catalog # BP2500a**Specification**

Myb Sumoylation Site Antibody Blocking Peptide - Product InformationPrimary Accession [P10242](#)**Myb Sumoylation Site Antibody Blocking Peptide - Additional Information****Gene ID** 4602**Other Names**

Transcriptional activator Myb, Proto-oncogene c-Myb, MYB

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP2500a](/product/products/AP2500a) was selected from the region of a human Myb sumoylation site. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Myb Sumoylation Site Antibody Blocking Peptide - Protein Information**Name** MYB**Function**

Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'. Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells.

Cellular Location

Nucleus {ECO:0000255|PROSITE-ProRule:PRU00625, ECO:0000269|PubMed:19646965}

Myb Sumoylation Site Antibody Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

Myb Sumoylation Site Antibody Blocking Peptide - Images

Myb Sumoylation Site Antibody Blocking Peptide - Background

Myb is a transcriptional activator; DNA-binding protein that recognizes the sequence 5'-YAAC[GT]G-3'. It participates in the control of proliferation and differentiation of hematopoietic progenitor cells. Myb is a transcription factor related to Myc, and is expressed predominantly in haematopoietic cells and immature gastroepithelial cells. TRAF7 stimulates the sumoylation of Myb at Lys-523 and Lys-499, which are the same sites as those used for PIASy-induced sumoylation. A correlation has been established between reduction in sumoylation of Myb and increase in transcriptional activation. Negative influence on transactivation properties by the negative regulatory domain region of c-Myb depends on upon sumoylation.

Myb Sumoylation Site Antibody Blocking Peptide - References

Luchetti, M.M., et al., J. Biol. Chem. 278(3):1533-1541 (2003). Dahle, O., et al., Eur. J. Biochem. 270(6):1338-1348 (2003). Chen, J., et al., Oncogene 21(12):1859-1869 (2002). Hernandez-Munain, C., et al., J. Immunol. 169(8):4362-4369 (2002). Tanno, B., et al., J. Biol. Chem. 277(26):23172-23180 (2002).